{"id":24625,"date":"2023-08-22T17:16:19","date_gmt":"2023-08-22T11:46:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24625"},"modified":"2023-08-22T17:17:46","modified_gmt":"2023-08-22T11:47:46","slug":"pharma-news-for-gilead-incannex-avidity","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity","title":{"rendered":"Eylea HD Injection 8 Mg Approved By FDA; Veopoz Receives FDA Approval for CHAPLE Disease Treatment; FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials; FDA Approval to Incannex\u2019s Sleep Apnoea Clinical Trial; FDA Orphan Drug Designation to Avidity\u2019s AOC 1044; Orphan Drug Designation to CanariaBio\u2019s MAb-AR20.5"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a068dbded7d0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a068dbded7d0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\/#Eylea_HD_Injection_8_Mg_Approved_By_FDA_for_Treatment_of_Wet_AMD_DME_and_Diabetic_Retinopathy\" >Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\/#Veopoz_Receives_FDA_Approval_as_the_First_Treatment_for_Children_and_Adults_With_CHAPLE_Disease\" >Veopoz Receives FDA Approval as the First Treatment for Children and Adults With CHAPLE Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\/#FDA_Places_Second_Partial_Clinical_Hold_on_AML_Enrollment_for_Magrolimab_Trials\" >FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\/#Incannex_Healthcare_Receives_US_FDA_Approval_For_Sleep_Apnoea_Clinical_Trial\" >Incannex Healthcare Receives US FDA Approval For Sleep Apnoea Clinical Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\/#Avidity_Receives_FDA_Orphan_Drug_Designation_for_AOC_1044_for_Treatment_of_Duchenne_Muscular_Dystrophy\" >Avidity Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\/#CanariaBio_Receives_FDAs_Orphan_Drug_Designation_for_MAb-AR205_Targeting_Pancreatic_Cancer\" >CanariaBio Receives FDA&#8217;s Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-eylea-hd-injection-8-mg-approved-by-fda-for-treatment-of-wet-amd-dme-and-diabetic-retinopathy\"><span class=\"ez-toc-section\" id=\"Eylea_HD_Injection_8_Mg_Approved_By_FDA_for_Treatment_of_Wet_AMD_DME_and_Diabetic_Retinopathy\"><\/span><strong>Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has approved <strong>Regeneron Pharmaceuticals\u2019<\/strong> <strong>EYLEA HD (aflibercept)<\/strong> Injection of 8 mg for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/wet-age-related-macular-degeneration-wet-amd-market\">treatment of patients with wet age-related macular degeneration (wAMD)<\/a>, diabetic macular edema (DME), and diabetic retinopathy. For all indications, the recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg\/mL solution) every 4 weeks (monthly) for the first 3 months, followed by 8 mg every 8 to 16 weeks (2 to 4 months) in wAMD and DME and every 8 to 12 weeks (2 to 3 months) for diabetic retinopathy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The FDA approval of EYLEA HD is an important advancement in retinal care,&#8221; said Peter Kaiser, M.D., Chaney Family Endowed Chair in Ophthalmology Research at the Cole Eye Institute and Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine. &#8220;With EYLEA HD, patients with wet age-related macular degeneration or diabetic retinal disease can now receive less frequent injections after their initial monthly doses while still experiencing EYLEA&#8217;s comparable visual gains, anatomic improvements, and safety profile.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA clearance is based on the 48-week findings of the <strong>PULSAR and PHOTON studies<\/strong>, which were two double-blind, active-controlled pivotal trials comparing EYLEA HD to <a href=\"https:\/\/www.delveinsight.com\/blog\/retinal-vein-occlusion-market-assessment\">EYLEA (aflibercept)<\/a> Injection 2 mg. Both the PULSAR trial in wAMD (N=1,009) and PHOTON trial in DME (N=658) met their primary endpoint, with EYLEA HD demonstrating non-inferior and clinically equivalent vision gains at 48 weeks with both 12- and 16-week dosing regimens after only 3 initial monthly doses, compared to an EYLEA 8-week dosing regimen after initial monthly doses (3 in PULSAR and 5 in PHOTON). The vast majority of patients who were randomly assigned to EYLEA HD 12- or 16-week dosage regimens (after three initial monthly doses) were able to sustain these treatment intervals for 48 weeks.<\/p>\n\n\n\n<p>EYLEA HD is being developed together by Regeneron and Bayer AG. Regeneron has exclusive rights to EYLEA and EYLEA HD in the United States. Bayer has licensed exclusive marketing rights outside of the United States, where the businesses will split revenues from EYLEA and EYLEA HD sales after regulatory approvals. Regulatory submissions for aflibercept 8 mg are being reviewed in Europe and Japan. Submissions to other regulatory authorities in other countries are also anticipated.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-veopoz-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-chaple-disease\"><span class=\"ez-toc-section\" id=\"Veopoz_Receives_FDA_Approval_as_the_First_Treatment_for_Children_and_Adults_With_CHAPLE_Disease\"><\/span><strong>Veopoz Receives FDA Approval as the First Treatment for Children and Adults With CHAPLE Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has approved <strong>Veopoz (pozelimab-bbfg)<\/strong> for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, according to Regeneron Pharmaceuticals, Inc. Veopoz is the first and only medicine approved for CHAPLE. The pre-approval inspection issues associated with the aflibercept 8 mg BLA have been addressed with the permission of Veopoz. The FDA is likely to take action on the aflibercept 8 mg BLA in the coming weeks.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Most patients with CHAPLE disease are children who face severely debilitating symptoms and often life-threatening complications that begin in infancy,&#8221; said Michael Lenardo, M.D., Chief, Molecular Development of the Immune System Section; Co-Director, Clinical Genomics Programme, National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH). &#8220;As an investigator in this pivotal trial and one of the disease&#8217;s discoverers, I witnessed firsthand the transformational clinical improvement that pozelimab achieves in CHAPLE patients.&#8221; The approval of pozelimab is a significant achievement, as it provides a new treatment that can benefit these long-suffering patients.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>CHAPLE is an extremely rare and potentially fatal genetic immunological disease caused by an overactive complement system. The complement system is a mechanism that kills microorganisms in healthy people. Those with CHAPLE, on the other hand, are unable to regulate complement activity due to CD55 gene alterations. Without correct CD55 regulation, the complement system may assault normal cells, causing damage to blood and lymph arteries in the upper digestive tract and resulting in protein loss. There are less than ten patients in the United States who have CHAPLE disease. Veopoz, a completely human monoclonal antibody, is intended to target complement factor C5, a protein involved in the activation of the complement system.<\/p>\n\n\n\n<p>The FDA approval is based on the findings of Phase II\/III open-label trial that looked at the efficacy and safety of pozelimab in 10 patients ranging in age from 3 to 19 years (median age of 8.5 years). On day one, patients received a single intravenous loading dose of pozelimab 30 mg\/kg, followed by weekly weight-based subcutaneous doses of pozelimab.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-places-second-partial-clinical-hold-on-aml-enrollment-for-magrolimab-trials\"><span class=\"ez-toc-section\" id=\"FDA_Places_Second_Partial_Clinical_Hold_on_AML_Enrollment_for_Magrolimab_Trials\"><\/span><strong>FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The enrollment of new patients in clinical trials within the United States, focusing on the potential groundbreaking <strong>anti-CD47 immunotherapy magrolimab<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\"><strong>acute myeloid leukemia (AML) treatment<\/strong><\/a>, has been partially halted again by the <strong>FDA<\/strong>. <strong>Gilead Sciences<\/strong> announced this development. The decision from the FDA comes after the discontinuation of the phase 3 ENHANCE trial (NCT04313881), which was assessing magrolimab in patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-with-excess-blasts2-market\"><strong>higher-risk myelodysplastic syndromes (HR-MDS)<\/strong><\/a>.<\/p>\n\n\n\n<p>Effective immediately, the screening and enrollment of fresh patients under the <strong>US investigational new drug application (IND 147229)<\/strong> and the <strong>US Expanded Access Program<\/strong> will be temporarily stopped. However, patients who are already participating in AML clinical trials investigating magrolimab will be permitted to continue their treatment and follow-up procedures as per the existing study protocol.<\/p>\n\n\n\n<p>The impacted trials encompass the <strong>phase 3 ENHANCE-2 trial (NCT04778397)<\/strong>, comparing the <strong>magrolimab <\/strong>and <strong>azacitidine combination against venetoclax (Venclexta)<\/strong> <strong>combined with azacitidine or intensive chemotherapy in treatment-na\u00efve patients with TP53-mutant AML<\/strong>. Also affected is the phase 3 ENHANCE-3 trial (NCT05079230), which is studying magrolimab along with <strong>venetoclax <\/strong>and <strong>azacitidine versus placebo in combination with venetoclax and azacitidine<\/strong> for AML treated patients unsuitable for chemotherapy.<\/p>\n\n\n\n<p>In <strong>January 2022<\/strong>, the <strong>FDA <\/strong>initially placed a partial clinical hold on all trials evaluating magrolimab in combination with azacytidine. However, in <strong>April 2022<\/strong>, following a comprehensive safety data review, the FDA lifted the clinical hold for trials involving the combination therapy for patients with MDS and AML.<\/p>\n\n\n\n<p>Globally, <strong>regulatory agencies<\/strong> and <strong>clinical trial investigators<\/strong> involved in these studies have been informed about the FDA&#8217;s decision. Importantly, trials exploring magrolimab&#8217;s use in <strong>solid tumors<\/strong> such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/head-and-neck-cancer-hnc-market\"><strong>head and neck cancer<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\"><strong>colorectal cancer<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>lung cancer<\/strong><\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-breast-cancer-market\"><strong>breast cancer<\/strong><\/a> will remain unaffected by this FDA action.<\/p>\n\n\n\n<p>Gilead is collaborating with regulatory agencies to outline the subsequent steps for resolving the partial clinical hold and recommencing new patient enrollment in <strong>AML-focused magrolimab studies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-incannex-healthcare-receives-us-fda-approval-for-sleep-apnoea-clinical-trial\"><span class=\"ez-toc-section\" id=\"Incannex_Healthcare_Receives_US_FDA_Approval_For_Sleep_Apnoea_Clinical_Trial\"><\/span><strong>Incannex Healthcare Receives US FDA Approval For Sleep Apnoea Clinical Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Incannex Healthcare Ltd<\/strong> has gained approval from the <strong>US Food and Drug Administration (FDA)<\/strong> to initiate a <strong>Phase 2\/3 clinical trial<\/strong> for its <strong>IHL-42X asset<\/strong>, developed to tackle <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\"><strong>obstructive sleep apnea<\/strong><\/a>. This clinical-stage pharmaceutical company, which specializes in creating proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies to address unmet medical needs, secured this endorsement after submitting an <strong>Investigational New Drug (IND)<\/strong> application to the FDA the previous month.<\/p>\n\n\n\n<p>The FDA, following an evaluation of the trial protocol, lead investigators, and a risk-benefit analysis of both the trial and the potential product, has sanctioned the clinical trial to proceed due to its deemed safety. With this significant achievement under its belt, Incannex will move forward with the completion of institutional review board applications and submissions for the primary clinical trial sites.<\/p>\n\n\n\n<p>The trial, spanning multiple centers, will explore the efficacy of <strong>IHL-42X as a treatment for OSA<\/strong> in patients who are either non-compliant, intolerant, or new to positive airway pressure treatments such as continuous positive airway pressure (CPAP) devices. Over the <strong>52-week treatment period<\/strong>, participants will be administered a single dose of <strong>IHL-42X, dronabinol, acetazolamide, or a placebo<\/strong>.<\/p>\n\n\n\n<p>Throughout the trial duration, participants will engage in daily sleep quality surveys and attend monthly clinic appointments to evaluate functional sleep outcomes, cognitive performance, and other safety and efficacy indicators. Polysomnography assessments will be conducted every three months to analyze the impact of treatment on parameters like the <strong>Apnoea Hypopnea Index (AHI)<\/strong> and other sleep-related metrics. The efficacy of all drug treatments will be compared against the effects of the placebo.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-avidity-receives-fda-orphan-drug-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy\"><span class=\"ez-toc-section\" id=\"Avidity_Receives_FDA_Orphan_Drug_Designation_for_AOC_1044_for_Treatment_of_Duchenne_Muscular_Dystrophy\"><\/span><strong>Avidity Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Avidity Biosciences, Inc. (Nasdaq: RNA) announced on August 15, 2023, that the U.S. Food and Drug Administration (FDA) has officially designated AOC 1044, the company&#8217;s investigational <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight\"><strong>treatment for Duchenne Muscular Dystrophy (DMD)<\/strong><\/a> in individuals with mutations suitable for exon 44 skipping (DMD44), as an Orphan Drug. Duchenne Muscular Dystrophy is an uncommon genetic disorder characterized by progressive muscle weakening and damage due to the absence of dystrophin protein, typically commencing at an early age. Presently, no approved treatments specifically target exon 44.<\/p>\n\n\n\n<p>Currently, undergoing evaluation in the Phase 1\/2 EXPLORE44\u2122 clinical trial, AOC 1044 is intended for individuals affected by DMD44 and represents the initial among numerous AOC compounds under development by Avidity to address <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\"><strong>Duchenne Muscular Dystrophy treatment<\/strong><\/a>. Avidity&#8217;s schedule includes the release of findings from the healthy volunteer segment of the EXPLORE44 trial in Q4 2023, while simultaneously enrolling DMD44 patients for the study. Notably, in April 2023, AOC 1044 was granted FDA Fast Track status for DMD44 therapy.<\/p>\n\n\n\n<p>AOC 1044 has been meticulously engineered to transport phosphorodiamidate morpholino oligomers (PMOs) to the muscles of the skeletal and cardiac systems. Its primary objective is to selectively omit exon 44 from the dystrophin gene, thereby fostering the production of dystrophin in <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-epidemiology-forecast\"><strong>individuals grappling with Duchenne Muscular Dystrophy<\/strong><\/a> marked by exon 44-skippable mutations (DMD44). The defining feature of Duchenne Muscular Dystrophy is gradual muscle deterioration and frailty, attributed to modifications in dystrophin\u2014a protein pivotal in shielding muscle cells from damage during contraction. AOC 1044 comprises an exclusive monoclonal antibody that attaches to transferrin receptor 1 (TfR1) and is fused with a PMO directed at exon 44.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>We are pleased that the FDA has granted both Orphan Drug and Fast Track designation to AOC 1044, highlighting the importance of advancing new treatments for people living with DMD. There are currently no treatment options that target the underlying cause of DMD44. AOC 1044 is designed to specifically skip exon 44 of the dystrophin gene to enable the production of functional dystrophin protein. We look forward to advancing AOC 1044 in clinical development and bringing this very important treatment to patients as quickly and safely as possible. Steve Hughes, M.D., chief medical officer at Avidity.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The EXPLORE44 trial, a Phase 1\/2 clinical study, employs a randomized, double-blind, placebo-controlled design to investigate the potential of AOC 1044. This trial encompasses both healthy volunteers and individuals harboring DMD mutations amenable to exon 44 skipping (DMD44). The primary objectives of EXPLORE44 encompass the evaluation of safety, tolerability, pharmacokinetics, and pharmacodynamic impacts of intravenous administration of AOC 1044 at various ascending dosages, encompassing both single and multiple doses. This trial is projected to encompass approximately 40 healthy volunteers and 24 participants, ranging in age from seven to 27 years old, who exhibit DMD44. EXPLORE44 will scrutinize the outcomes of exon skipping and the levels of dystrophin protein within the cohort of DMD44 participants. Moreover, those individuals afflicted with DMD44 will be given the opportunity to participate in an extension study as part of the trial.<\/p>\n\n\n\n<p>Duchenne Muscular Dystrophy is a devastating genetic disorder that primarily affects young boys. Duchenne Muscular Dystrophy stands as the most prevalent form of muscular dystrophy. It is characterized by progressive muscle degeneration and weakness due to the absence of a protein called dystrophin, which plays a crucial role in maintaining the structural integrity of muscle fibers. As a result, affected individuals experience difficulties in walking, moving, and performing daily tasks as their muscles gradually weaken. It primarily affects males, with one in 3,500 to 5,000 boys born worldwide having Duchenne Muscular Dystrophy. While there is currently no cure for Duchenne Muscular Dystrophy, advancements in medical research have led to the development of therapies aimed at managing the symptoms and improving the quality of life for affected individuals. These include approaches such as exon skipping and gene therapy, which seek to restore the production of functional dystrophin protein or its equivalents.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-canariabio-receives-fda-s-orphan-drug-designation-for-mab-ar20-5-targeting-pancreatic-cancer\"><span class=\"ez-toc-section\" id=\"CanariaBio_Receives_FDAs_Orphan_Drug_Designation_for_MAb-AR205_Targeting_Pancreatic_Cancer\"><\/span><strong>CanariaBio Receives FDA&#8217;s Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CanariaBio Inc. announced on August 21, 2023, that the U.S. Food and Drug Administration (FDA) has officially designated its investigational drug product, MAb-AR20.5, as an orphan drug designation. MAb-AR20.5 is a murine monoclonal antibody of the IgG1k type, designed to selectively bind to the circulating and tumor-associated antigen (MUC1), which is present universally on Pancreatic Cancer cells. This achievement is noteworthy as it represents the inaugural monoclonal antibody aimed at Mucin 1 (MUC1) to be granted orphan drug designation for Pancreatic Cancer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;Receiving Orphan Drug Designation for MAb-AR20.5 is a significant milestone for CanariaBio Inc. and speaks to the potential promise of this novel therapeutic approach,&#8221; said Mike Na, the CEO of CanariaBio Inc. &#8220;We are deeply committed to advancing innovative <a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-pipeline-insight\"><strong>treatments for patients with Pancreatic Cancer<\/strong><\/a> and remain hopeful that MAb-AR20.5 will offer a new lifeline for those affected.&#8221;<\/p>\n<\/blockquote>\n\n\n\n<p>The MAb-AR20.5 has shown potential in early studies, by inducing MUC-1-specific immune responses in cancer patients with advanced disease. This specific targeting aims to provide a more focused and potentially more effective treatment strategy for patients diagnosed with this aggressive disease. CanariaBio Inc. is planning to initiate clinical trials to assess the safety and efficacy of MAb-AR20.5 in patients with Pancreatic Cancer. More details about the upcoming studies and trial sites will be made available in the coming months.<\/p>\n\n\n\n<p>In initial investigations, MAb-AR20.5 has exhibited promise by eliciting immune responses tailored to MUC-1 in individuals with advanced-stage cancer. This precise targeting approach strives to offer a more concentrated and potentially enhanced therapeutic approach for individuals confronting this aggressive ailment. CanariaBio Inc. is in the process of preparing to commence clinical trials aimed at evaluating the safety and effectiveness of MAb-AR20.5 in individuals diagnosed with Pancreatic Cancer. The CanariaBio will provide further information regarding the upcoming research endeavors and the locations of the trials in the forthcoming months.<\/p>\n\n\n\n<p>Pancreatic Cancer remains one of the most challenging malignancies to treat, with limited therapeutic options available. As per DelveInsight, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-epidemiology-forecast\"><strong>total incident cases of Pancreatic Cancer<\/strong><\/a> in the 7MM were 180,000 in 2022, which is expected to increase in the upcoming years. In 2022, Germany had the highest number of cases, accounting for 30% of cases in EU4 and the UK. Whereas, Spain accounted for the least number of cases in the EU4 and the UK region. While, Japan accounted for 45,000 incident cases of Pancreatic Cancer, which was approximately 25% of the total Pancreatic Cancer cases in 7MM. Globally, several companies are actively working in the<a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\" class=\"ek-link\"><strong> Pancreatic Cancer therapeutics market<\/strong><\/a> to improve the treatment dynamics.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals\u2019 EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy. For all indications, the recommended dose for [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":24628,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18089,21207,107,21208,21204,1805,1796,704,21205,349,420,19756,449,639,5789,504,21206],"industry":[17225],"therapeutic_areas":[17240,17238,17228,17244,17234,17506],"class_list":["post-24625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-myeloid-leukemia","tag-avidity","tag-bayer","tag-canariabio","tag-chaple-disease","tag-diabetic-retinopathy","tag-duchenne-muscular-dystrophy","tag-fda","tag-incannex","tag-latest-pharma-news","tag-news","tag-orphan-drug-designation","tag-pancreatic-cancer","tag-pharma-news","tag-recent-pharma-news","tag-regeneron","tag-sleep-apnoea","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-ophthalmology","therapeutic_areas-rare-diseases","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Regeneron, Gilead, Incannex, Avidity, CanariaBio<\/title>\n<meta name=\"description\" content=\"Eylea HD Injection 8 Mg; CHAPLE Disease Treatment Approval; Gilead&#039;s Magrolimab Trials; Avidity\u2019s AOC 1044; CanariaBio\u2019s MAb-AR20.5; Incannex\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Regeneron, Gilead, Incannex, Avidity, CanariaBio\" \/>\n<meta property=\"og:description\" content=\"Eylea HD Injection 8 Mg; CHAPLE Disease Treatment Approval; Gilead&#039;s Magrolimab Trials; Avidity\u2019s AOC 1044; CanariaBio\u2019s MAb-AR20.5; Incannex\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-22T11:46:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-22T11:47:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/22171505\/Pharma-News-for-Gilead-Incannex-Avidity.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Regeneron, Gilead, Incannex, Avidity, CanariaBio","description":"Eylea HD Injection 8 Mg; CHAPLE Disease Treatment Approval; Gilead's Magrolimab Trials; Avidity\u2019s AOC 1044; CanariaBio\u2019s MAb-AR20.5; Incannex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Regeneron, Gilead, Incannex, Avidity, CanariaBio","og_description":"Eylea HD Injection 8 Mg; CHAPLE Disease Treatment Approval; Gilead's Magrolimab Trials; Avidity\u2019s AOC 1044; CanariaBio\u2019s MAb-AR20.5; Incannex","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-08-22T11:46:19+00:00","article_modified_time":"2023-08-22T11:47:46+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/22171505\/Pharma-News-for-Gilead-Incannex-Avidity.webp","type":"image\/webp"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity","name":"Pharma News | Regeneron, Gilead, Incannex, Avidity, CanariaBio","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/22171505\/Pharma-News-for-Gilead-Incannex-Avidity.webp","datePublished":"2023-08-22T11:46:19+00:00","dateModified":"2023-08-22T11:47:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Eylea HD Injection 8 Mg; CHAPLE Disease Treatment Approval; Gilead's Magrolimab Trials; Avidity\u2019s AOC 1044; CanariaBio\u2019s MAb-AR20.5; Incannex","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-incannex-avidity#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/22171505\/Pharma-News-for-Gilead-Incannex-Avidity.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/22171505\/Pharma-News-for-Gilead-Incannex-Avidity.webp","width":772,"height":482,"caption":"Pharma News for Gilead, Incannex, Avidity"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/22171505\/Pharma-News-for-Gilead-Incannex-Avidity-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Myeloid Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Avidity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CanariaBio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CHAPLE Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">diabetic retinopathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Incannex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orphan Drug Designation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sleep Apnoea<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Myeloid Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Avidity<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">CanariaBio<\/span>","<span class=\"advgb-post-tax-term\">CHAPLE Disease<\/span>","<span class=\"advgb-post-tax-term\">diabetic retinopathy<\/span>","<span class=\"advgb-post-tax-term\">Duchenne muscular dystrophy<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Incannex<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Orphan Drug Designation<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">Sleep Apnoea<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Aug 22, 2023","modified":"Updated on Aug 22, 2023"},"absolute_dates_time":{"created":"Posted on Aug 22, 2023 5:16 pm","modified":"Updated on Aug 22, 2023 5:17 pm"},"featured_img_caption":"Pharma News for Gilead, Incannex, Avidity","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24625"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/24628"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24625"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24625"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}